Seeking Alpha

More on Vivus earnings

  • Vivus (VVUS) Q2 comes in below estimates.
  • Net product revenue was $5.5M, versus a flatline last year.
  • Net losses increased Y/Y, primarily due to increased SG&A expenses related to commercialization activities for Qsymia.
  • Approximately 81K Qsymia prescriptions were dispensed during the quarter, of which approximately 24K were dispensed under the Free Trial Offer.
  • All of these prescriptions were dispensed through the certified mail order home delivery system.
  • Shares unchanged AH.
From other sites
Comments (1)
  • user418
    , contributor
    Comments (249) | Send Message
     
    Short VVUS and go long ARNA !!!
    6 Aug 2013, 05:37 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs